John G. Saia

CLO John G. Saia sold 10,000 shares at $125.08 blended average, reducing holdings 21.8% via scheduled 10b5-1 plan.

John G. Saia, Chief Legal Officer at Guardant Health, executed 2 separate sales totaling 10,000 shares for $1,250,835.98 on 2026-05-27 under a pre-arranged 10b5-1 trading plan. The sale reduced his holdings from 45,950 shares to 35,950 shares (a 21.8% reduction). This transaction is scheduled under a 10b5-1 plan, not a discretionary decision, so it reflects plan timing rather than active strategic positioning. Guardant Health trades at $133.22 currently, above the 52-week high of $128.00 and up 60.3% over 30 days and 41.9% over 90 days, while the company posted negative net income of $-112,075,000.00 despite revenue growth of 32.9% annually.

GH CLO John G. Saia sells 20,000 shares for $2.1M via 10b5-1 plan; current price $118.95 vs $106.51 blended sale price

Chief Legal Officer John G. Saia executed 3 separate sales totaling 20,000 shares for $2,130,228.98 on 2026-05-20 at prices ranging from $105.34 to $107.23, under a pre-arranged 10b5-1 trading plan. As scheduled trades, these sales do not reflect discretionary timing decisions by the insider. His post-transaction holdings stand at 45,950 shares, representing a -30.3% reduction versus pre-transaction holdings of 65,950 shares. The company is unprofitable with net income of $-112,075,000.00 over its most recent full fiscal year, though revenue reached $301,665,000.00 and grew +32.9% year-over-year, indicating expansion amid ongoing losses.

GH Chief Legal Officer sold 8,996 shares at $96.25; stock up 52.5% in 30 days amid losses.

Saia John G., Chief Legal Officer of Guardant Health, sold 8,996 shares (9.0K shares) at $96.25, reducing holdings by -17.2% from 52.2K to 43.2K shares. The sale occurred during a period of exceptional share price appreciation: the stock rose 52.5% over 30 days and 77.7% over 90 days, currently trading at $97.92, within 1.0% of its 52-week high of $98.92. While the company posted strong revenue growth of +31.0% year-over-year to $265.2M in the latest quarter, it remains unprofitable with a full-year net income of $-92.7M. The transaction follows a sustained rally without clear evidence of fundamental inflection toward profitability, warranting attention to whether this sale represents material insider reassessment of valuation at elevated price levels.